{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:50:37Z","timestamp":1783471837553,"version":"3.55.0"},"reference-count":56,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"vor","delay-in-days":1461,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1038\/ki.2013.264","type":"journal-article","created":{"date-parts":[[2013,7,3]],"date-time":"2013-07-03T12:39:09Z","timestamp":1372855149000},"page":"874-879","source":"Crossref","is-referenced-by-count":39,"title":["Hepatitis C treatment in patients with kidney disease"],"prefix":"10.1016","volume":"84","author":[{"given":"Fabrizio","family":"Fabrizi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Aghemo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piergiorgio","family":"Messa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/ki.2013.264_bb0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000332374","article-title":"Hepatitis C: epidemiology, diagnosis, natural history and therapy","volume":"176","author":"Pol","year":"2012","journal-title":"Contrib Nephrol"},{"key":"10.1038\/ki.2013.264_bb0015","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1159\/000333761","article-title":"Hepatitis C in haemodialysis: epidemiology and prevention of hepatitis C virus transmission","volume":"176","author":"Jadoul","year":"2012","journal-title":"Contrib Nephrol"},{"key":"10.1038\/ki.2013.264_bb0020","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1111\/j.1523-1755.2004.00649.x","article-title":"Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: The DOPPS","volume":"65","author":"Fissell","year":"2004","journal-title":"Kidney Int"},{"issue":"Suppl 109","key":"10.1038\/ki.2013.264_bb0025","first-page":"S1","article-title":"KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease","volume":"73","author":"Kidney Disease: Improving Global Outcomes","year":"2008","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2013.264_bb0030","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/j.1365-2893.2012.01633.x","article-title":"Impact of hepatitis C on survival in dialysis patients: a link with cardiovascular mortality?","volume":"19","author":"Fabrizi","year":"2012","journal-title":"J Viral Hepat"},{"key":"10.1038\/ki.2013.264_bb0035","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1097\/01.ASN.0000100127.54107.57","article-title":"Association of comorbid conditions and mortality in haemodialysis patients in Europe, Japan, and the United States: the dialysis outcomes, and practice patterns","volume":"14","author":"Goodkin","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2013.264_bb0040","first-page":"345","article-title":"Hepatitis C virus infection as a risk factor for increased aortic stiffness and cardiovascular events in dialysis patients","volume":"21","author":"Oyake","year":"2008","journal-title":"J Nephrol"},{"key":"10.1038\/ki.2013.264_bb0045","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1681\/ASN.2010060668","article-title":"Effect of kidney transplantation on outcomes among patients with hepatitis C","volume":"22","author":"Roth","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2013.264_bb0050","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1097\/00007890-199610270-00004","article-title":"The high prevalence of severe early post-transplant renal allograft pathology in hepatitis C positive recipients","volume":"62","author":"Cosio","year":"1996","journal-title":"Transplantation"},{"key":"10.1038\/ki.2013.264_bb0055","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1034\/j.1600-6143.2001.10212.x","article-title":"Hepatitis C virus infection and de novo glomerular lesions in renal allografts","volume":"1","author":"Cruzado","year":"2001","journal-title":"Am J Transplant"},{"key":"10.1038\/ki.2013.264_bb0060","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1097\/00007890-199706150-00017","article-title":"Membranous glomerulonephritis associated with hepatitis C virus infection in renal transplant patients","volume":"63","author":"Morales","year":"1997","journal-title":"Transplantation"},{"key":"10.1038\/ki.2013.264_bb0065","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1097\/00007890-199506270-00006","article-title":"De novo membrano-proliferative glomerulonephritis in hepatitis C virus-infected renal allograft recipients","volume":"59","author":"Roth","year":"1995","journal-title":"Transplantation"},{"key":"10.1038\/ki.2013.264_bb0070","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1097\/01.ASN.0000012382.97168.E0","article-title":"Association of hepatitis C with post-transplant diabetes in renal transplant patients on tacrolimus","volume":"13","author":"Bloom","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2013.264_bb0075","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/j.1399-0012.2004.00256.x","article-title":"Cyclosporine pharmacokinetics in anti-HCV positive patients","volume":"18","author":"Wolffenbuttel","year":"2004","journal-title":"Clin Transplant"},{"key":"10.1038\/ki.2013.264_bb0080","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1097\/01.ASN.0000145896.16153.43","article-title":"Hepatitis C, acute humoral rejection, and renal allograft survival","volume":"15","author":"Forman","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2013.264_bb0085","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1111\/j.1600-6143.2005.01230.x","article-title":"Subclinical rejection associated with chronic allograft nephropathy in protocol biopsies as a risk factor for late graft loss","volume":"6","author":"Moreso","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1038\/ki.2013.264_bb0090","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1034\/j.1600-6143.2003.00057.x","article-title":"Pretransplant interferon prevents hepatitis C virus-associated glomerulonephritis in renal allografts by HCV RNA clearance","volume":"3","author":"Cruzado","year":"2003","journal-title":"Am J Transplant"},{"key":"10.1038\/ki.2013.264_bb0095","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S0041-1345(00)00890-3","article-title":"Impact of HCV infection on development of posttransplantation diabetes mellitus in renal allograft recipients","volume":"32","author":"Gursoy","year":"2000","journal-title":"Transplant Proc"},{"key":"10.1038\/ki.2013.264_bb0100","doi-asserted-by":"crossref","first-page":"c133","DOI":"10.1159\/000085442","article-title":"Interferon therapy in hemodialysis patients with chronic hepatitis C: study of tolerance, efficacy and post-transplantation course","volume":"100","author":"Mahmoud","year":"2005","journal-title":"Nephron Clin Pract"},{"key":"10.1038\/ki.2013.264_bb0105","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1365-2893.2008.00990.x","article-title":"Interferon mono-therapy of chronic hepatitis C in dialysis patients: meta-analysis of clinical trials","volume":"15","author":"Fabrizi","year":"2008","journal-title":"J Viral Hepat"},{"key":"10.1038\/ki.2013.264_bb0110","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1002\/hep.20119","article-title":"American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C","volume":"39","author":"Strader","year":"2004","journal-title":"Hepatology"},{"key":"10.1038\/ki.2013.264_bb0115","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2b plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"Fried","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1038\/ki.2013.264_bb0120","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"key":"10.1038\/ki.2013.264_bb0125","doi-asserted-by":"crossref","first-page":"346","DOI":"10.7326\/0003-4819-140-5-200403020-00010","article-title":"Pegasys International Study Group. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose","volume":"140","author":"Hadziyannis","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1038\/ki.2013.264_bb0130","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1681\/ASN.V9122344","article-title":"Pharmacokinetics of alphaIFN-2b in chronic hepatitis C virus patients undergoing chronic haemodialysis or with normal renal function: clinical implications","volume":"9","author":"Rostaing","year":"1998","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2013.264_bb0135","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1111\/j.1365-2893.2010.01405.x","article-title":"Combined antiviral therapy of hepatitis C virus in dialysis patients: meta-analysis of clinical trials","volume":"18","author":"Fabrizi","year":"2011","journal-title":"J Viral Hepat"},{"key":"10.1038\/ki.2013.264_bb0140","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1159\/000333775","article-title":"Treatment of hepatitis C virus infection after kidney transplantation","volume":"176","author":"Rostaing","year":"2012","journal-title":"Contrib Nephol"},{"key":"10.1038\/ki.2013.264_bb0145","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1056\/NEJMoa0806104","article-title":"PROVE1 Study Team. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection","volume":"360","author":"McHutchison","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1038\/ki.2013.264_bb0150","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1056\/NEJMoa0807650","article-title":"PROVE2 Study Team. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection","volume":"360","author":"Hezode","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1038\/ki.2013.264_bb0155","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1002\/hep.24641","article-title":"An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guidelines by the American Association for the Study of Liver Diseases","volume":"54","author":"Ghany","year":"2011","journal-title":"Hepatology"},{"key":"10.1038\/ki.2013.264_bb0160","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1046\/j.1523-1755.1998.00883.x","article-title":"Effects of hepatitis C infection and renal transplantation on survival","volume":"53","author":"Pereira","year":"1998","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2013.264_bb0165","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0272-6386(98)70027-7","article-title":"Risk of death among chronic dialysis patients infected with hepatitis C virus","volume":"32","author":"Stehman-Breen","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/ki.2013.264_bb0170","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1681\/ASN.V11101896","article-title":"Prognosis of anti-hepatitis C virus antibody-positive patients on regular hemodialysis therapy","volume":"11","author":"Nakayama","year":"2000","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2013.264_bb0175","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1093\/ndt\/16.8.1669","article-title":"Risk of death and liver cirrhosis in anti-HCV-positive long-term haemodialysis patients","volume":"16","author":"Espinosa","year":"2001","journal-title":"Nephrol Dial Transplant"},{"key":"10.1038\/ki.2013.264_bb0180","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1053\/j.ajkd.2006.07.004","article-title":"Lazio Dialysis Registry. Epidemiology of hepatitis C virus among long-term dialysis patients: a 9-year study in an Italian region","volume":"48","author":"Di Napoli","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/ki.2013.264_bb0185","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1681\/ASN.2006070736","article-title":"Hepatitis C virus and death risk in hemodialysis patients","volume":"18","author":"Kalantar-Zadeh","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2013.264_bb0190","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1177\/089686080802800215","article-title":"Mortality in hepatitis C-positive patients treated with peritoneal dialysis","volume":"28","author":"Wang","year":"2008","journal-title":"Perit Dial Int"},{"key":"10.1038\/ki.2013.264_bb0195","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1093\/ndt\/gfn684","article-title":"Frequencies of hepatitis B and C infections among haemodialysis and peritoneal dialysis patients in Asia-Pacific countries: analysis of registry data","volume":"24","author":"Johnson","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1038\/ki.2013.264_bb0200","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1097\/TP.0b013e3181f92548","article-title":"Adverse impact of hepatitis C virus infection on renal replacement therapy and renal transplant patients in Australia and New Zealand","volume":"90","author":"Scott","year":"2010","journal-title":"Transplantation"},{"key":"10.1038\/ki.2013.264_bb0205","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2188\/jea.JE20100187","article-title":"Seropositivity for anti-HCV core antigen is independently associated with increased all-cause, cardiovascular, and liver disease-related mortality in hemodialysis patients","volume":"21","author":"Ohsawa","year":"2011","journal-title":"J Epidemiol"},{"key":"10.1038\/ki.2013.264_bb0210","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.cgh.2010.10.018","article-title":"Low-dose peginterferon alfa-2a is safe and produces a sustained virologic response in patients with chronic hepatitis C and end-stage renal disease","volume":"9","author":"Peck-Radosavljevic","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1038\/ki.2013.264_bb0215","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1159\/000322922","article-title":"Pegylated interferon for treatment of chronic hepatitis C in hemodialysis patients in Croatia","volume":"34","author":"Basic-Jukic","year":"2011","journal-title":"Kidney Blood Press Res"},{"key":"10.1038\/ki.2013.264_bb0220","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s15010-008-7134-z","article-title":"The response to pegylated interferon alpha 2a in haemodialysis patients with hepatitis C virus infection","volume":"36","author":"Akhan","year":"2008","journal-title":"Infection"},{"key":"10.1038\/ki.2013.264_bb0225","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3748\/wjg.14.255","article-title":"Efficacy and safety of pegylated-interferon alpha-2a in hemodialysis patients with chronic hepatitis C","volume":"14","author":"Ayaz","year":"2008","journal-title":"World J Gastroenterol"},{"key":"10.1038\/ki.2013.264_bb0230","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1080\/08860220701641579","article-title":"Treatment of hepatitis C in hemodialysis patients with pegylated interferon alpha-2a as monotherapy","volume":"29","author":"Sikole","year":"2007","journal-title":"Renal Fail"},{"key":"10.1038\/ki.2013.264_bb0235","doi-asserted-by":"crossref","first-page":"366","DOI":"10.5414\/CNP67366","article-title":"Anemia associated with pegylated interferon-alpha2a and alpha2b therapy in haemodialysis patients","volume":"6","author":"Espinosa","year":"2007","journal-title":"Clin Nephrol"},{"key":"10.1038\/ki.2013.264_bb0240","first-page":"794","article-title":"Analysis of safety and efficacy of pegylated-interferon alpha-2a in hepatitis C virus positive hemodialysis patients: results from a large multicenter audit","volume":"19","author":"Covic","year":"2006","journal-title":"J Nephrol"},{"key":"10.1038\/ki.2013.264_bb0245","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1093\/ndt\/gfi231","article-title":"Randomized trial of pegylated interferon alpha-2b monotherapy in hemodialysis patients with chronic hepatitis C","volume":"21","author":"Russo","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"10.1038\/ki.2013.264_bb0250","doi-asserted-by":"crossref","first-page":"4191","DOI":"10.3748\/wjg.v12.i26.4191","article-title":"Pegylated interferon alpha2a treatment for chronic hepatitis C in patients on chronic haemodialysis","volume":"12","author":"Sporea","year":"2006","journal-title":"World J Gastroenterol"},{"key":"10.1038\/ki.2013.264_bb0255","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.jhep.2006.12.016","article-title":"The treatment of chronic hepatitis C with pegylated interferon alpha2a (40 kDa) plus ribavirin in hemodialysed patients awaiting renal transplant","volume":"46","author":"Rendina","year":"2007","journal-title":"J Hepatol"},{"key":"10.1038\/ki.2013.264_bb0260","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1177\/039139880803100404","article-title":"Treatment of dialysis patients with chronic hepatitis C using pegylated interferon and low dose ribavirin","volume":"31","author":"Carriero","year":"2008","journal-title":"Int J Artif Organs"},{"key":"10.1038\/ki.2013.264_bb0265","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1093\/ndt\/gfm724","article-title":"Pegylated interferon alfa-2a (40 kDa) and ribavirin in haemodialysis patients with chronic hepatitis C","volume":"23","author":"Van Leusen","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"10.1038\/ki.2013.264_bb0270","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/MCG.0b013e318180803a","article-title":"HCV response in patients with end stage renal disease treated with combination pegylated interferon alpha-2a and ribavirin","volume":"43","author":"Hakim","year":"2009","journal-title":"J Clin Gastroenterol"},{"key":"10.1038\/ki.2013.264_bb0275","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1136\/gut.2008.165076","article-title":"Pegylated interferon alpha-2a plus low-dose ribavirin for the retreatment of dialysis chronic hepatitis C patients who relapsed from prior interferon monotherapy","volume":"58","author":"Liu","year":"2009","journal-title":"Gut"},{"key":"10.1038\/ki.2013.264_bb0280","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/j.1365-2036.2011.04741.x","article-title":"Antiviral therapy in haemodialysed HCV patients: efficacy, tolerance and treatment strategy","volume":"34","author":"Deltenre","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1038\/ki.2013.264_bb0285","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.ejim.2011.05.008","article-title":"Treatment of hepatitis C virus infection in patients on maintenance hemodialysis: a single United Arab Emirates center experience","volume":"22","author":"Giguere","year":"2011","journal-title":"Eur J Intern Med"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S008525381556078X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S008525381556078X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,2,27]],"date-time":"2022-02-27T04:05:34Z","timestamp":1645934734000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S008525381556078X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":56,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["S008525381556078X"],"URL":"https:\/\/doi.org\/10.1038\/ki.2013.264","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11]]}}}